Daratumumab treatment for certain relapsed blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This Phase 2 trial studies daratumumab (an antibody medicine) for adults whose rare lymph node/immune-related cancers have come back or did not respond to treatment. It may help shrink disease and improve symptoms, including for people living with HIV when their virus is well controlled.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older and have one of these diagnoses: primary effusion lymphoma, plasmablastic lymphoma, or KSHV-associated multicentric Castleman disease
- Your cancer/illness has relapsed or did not respond (is “refractory”), or you cannot receive first-line chemotherapy
- You have measurable or assessable disease (if you have primary effusion lymphoma or plasmablastic lymphoma)
- Your body condition is good enough for treatment (ECOG performance status 0–2, or 3 only if caused by the lymphoma/Castleman disease), and your blood counts and kidneys meet minimum levels
- If you have HIV: you must be on an effective combination ART regimen and your HIV viral load is under 200 copies/mL
- If you have active hepatitis B: you must be on treatment that keeps the virus suppressed; if you have hepatitis C: you must have finished treatment and have an undetectable viral load for at least 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with multiple myeloma or AL amyloidosis who are about to start treatment with a drug called daratumumab. It compares two places to inject the medicine (thigh vs. abdomen) to see which works better and is more comfortable.
This Phase 2 trial tests daratumumab (a targeted antibody medicine) in people with T-cell ALL whose leukemia is not fully gone at very low levels. The goal is to eliminate “minimal residual disease” (MRD) that can predict relapse, so treatment may be more effective after intensive chemotherapy.
This trial tests if adding the drug daratumumab can clear remaining cancer cells in people with T-cell acute lymphoblastic leukemia (T-ALL) who still have a small amount of leukemia after initial chemotherapy. It aims to reduce the risk of the cancer coming back.
This Phase 2 study tests whether adding daratumumab to standard chemotherapy, followed by a stem cell transplant, can improve outcomes in primary plasma cell leukemia. It aims to see how well this treatment works and whether it’s safe for people who are eligible for intensive therapy and transplant.
This trial tests if daratumumab, a targeted antibody therapy, can help patients with aplastic anemia that hasn't improved after standard treatments. It's for adults who cannot or choose not to have a stem cell transplant.
This early-phase trial tests daratumumab combined with a dose-adjusted chemotherapy plan (EPOCH) to treat plasmablastic lymphoma. It aims to improve how well the cancer responds, including in people living with HIV or without HIV.
Hear when a new Lymphoma, Primary Effusion trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.